NeoPhore
PrivateLast Round
Series B
Extension
May 22, 2024
Total Funding Raised
$68.42M
Company Overview
NeoPhore is a biotechnology company that develops small molecule immuno-oncology therapies targeting the DNA mismatch repair pathway to stimulate the immune system against cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
NeoPhore Comparables
Compare NeoPhore with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Grey Wolf Therapeutics | 78% | |
| Artios Pharma | 75% | |
| FoRx Therapeutics | 75% | |
NeoPhore Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | May 22, 2024 | ||||
| Series B Extension | Jan 19, 2023 | ||||
| Series B | Mar 9, 2021 | ||||
| Grant | Apr 27, 2018 | ||||
| Seed | Nov 1, 2017 |
Key People
Founding team and executive leadership
NeoPhore Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| 3B FUTURE Health Fund | Series B, Series B Extension |
| Neva SGR | Series B, Series B Extension |
| Sixth Element Capital | Seed |
| Claris Ventures | Series B Extension, Series B |
| 2invest AG | Series B, Series B Extension |
| Simon Fiduciaria | Series B, Series B Extension |
| Astellas Venture Management | Series B, Series B Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 1, 2025
CEO presented at the Morgan Stanley Global Healthcare Conference on September 1, 2025.
- Jan 1, 2025
Partnering with Memorial Sloan Kettering Cancer Center via scientific founder Dr. Luis Diaz.
NeoPhore Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about NeoPhore's valuation, stock price, and market status.